The market launch of Ziflucort, a hormonal drug product for chronic adrenal failure at the end of 2022 is one of the company's successful examples of implementing of the Import Substitution Program of the Russian Ministry of Industry and Trade in order to strengthen the country's drug supply system.

It should be noted that the Pharmasyntez Group of Companies, anticipating future problems with the supply of foreign hormonal drugs to the Russian market, has been actively implementing a project to create large-scale production of hormones in Russia at the Tyumen plant over the past few years.

Pharmasyntez-Tyumen is the country's manufacturing site unique in its scale and capabilities, which specializes in the production of a wide range of hormonal drugs in different dosage forms.

New dosage forms of hormonal drugs are being actively developed and introduced into production at the site. For example, transdermal forms of estrogens are planned to be launched.